GlassScriptPhysician profile
Andrew Morris
NPI 1326135682
$2,301.01
in general payments reported to CMS, 2019-2025
14 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $779 · 2020: $76.15 · 2021: $134 · 2022: $28.33 · 2023: $399 · 2024: $430 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189 · Education: $94.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.69 |
| Education | $94.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $464.09 | 2019-2024 | Aristada, Lybalvi, Aristada Initio |
| E.R. Squibb & Sons, L.L.C. | $357.49 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $351.36 | 2019-2021 | |
| Abbvie INC. | $308.46 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $245.57 | 2019-2024 | Spravato |
| Lundbeck LLC | $169.48 | 2024-2025 | Rexulti |
| Allergan, INC. | $163.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $79.50 | 2025 | |
| Axsome Therapeutics, INC. | $71.68 | 2024-2025 | Auvelity |
| Braeburn INC. | $39.81 | 2025 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $17.57 | 2024 | Trintellix |
| Indivior INC. | $12.84 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $11.91 | 2019 | |
| Corium, LLC | $7.42 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.